The panel recommends stratifying all patients into low- and high-risk categories for rebleeding and mortality. They suggest blood transfusions for patients with hemoglobin levels less than 70 g/L. They recommend early endoscopy for most patients and recommend against routine use of promotility agents before endoscopy. They advise endoscopic hemostasis treatment of high-risk lesions, intravenous high-dose proton-pump inhibitor (PPI) therapy after successful endoscopic hemostasis, and hospitalization for at least 72 hours after endoscopic hemostasis. Patients at low risk for rebleeding on the basis of clinical characteristics and endoscopic findings can be discharged promptly after endoscopy. All patients should be tested for Helicobacter pylori infection, but if negative test results are obtained in the acute setting, then tests should be repeated. Routine second-look endoscopy is not recommended. The panel advises combining a PPI with a cyclooxygenase-2 inhibitor for patients who have experienced bleeding while receiving a nonsteroidal anti-inflammatory drug (NSAID) yet require long-term NSAID therapy to reduce the risk for recurrent bleeding. They also advise restarting acetylsalicylic acid (ASA) therapy for secondary cardiovascular prophylaxis as soon as cardiovascular risks outweigh gastrointestinal risks (usually within 7 days). Finally, they note that ASA plus a PPI is preferred over clopidogrel alone to reduce risk for recurrent bleeding.